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Abstract
Background—Although consensus guidelines for eosinophilic esophagitis (EoE) have been
published, it is unclear whether gastroenterologists follow these recommendations.
Aim—To assess academic and community practice patterns for the evaluation and treatment of
EoE and to compare these practices with current guidelines.
Methods—This was a prospective study of academic and community gastroenterologists using a
self-administered online survey.
Results—A total of 60% (34 of 57) of academic and 29% (38 of 133) of community
gastroenterologists completed the survey. Only 24% of academic and 3% of community
gastroenterologists follow consensus guidelines to diagnose EoE (p=0.007). A proton pump
inhibitor trial or negative pH study prior to diagnosis was required by just 25% of all
gastroenterologists. The majority (60%) do not use the recommended threshold of 15 eosinophils
per high powered field to diagnosis EoE. Half (51%) mistakenly require a positive endoscopic
finding. For first line treatment, about half of the gastroenterologists surveyed treat with a
swallowed topical steroid (53% academic, 56% community; p=NS), consistent with the
guidelines.
Conclusions—There is variability in practice patterns for both diagnosis and treatment of EoE.
Ongoing education and research concerning diagnosis and treatment is needed.
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Eosinophilic esophagitis (EoE) is a chronic allergic disease of the esophagus characterized
by dysphagia and food impaction in adults.(1) This once rare diagnosis has become
increasingly common, with various authors crediting a combination of growing awareness
and increased incidence.(2–7) Given the initial heterogeneity of disease definitions (8) and
rapidly evolving knowledge base for this disease, consensus guidelines for the diagnosis and
treatment of EoE were published in 2007.(1)
According to these guidelines, a diagnosis of EoE should be made when a patient presents
with symptoms of esophageal dysfunction and esophageal biopsy demonstrates 15 or more
eosinophils in a high power field (eos/hpf) in the absence of competing causes such as
gastroesophageal reflux disease (GERD).(1) To rule out GERD, a trial of a high dose
proton-pump inhibitor (PPI) therapy or pH monitoring is recommended.(1) For treatment,
guidelines recommend swallowed topical corticosteroids for mild to moderate cases or a
finite course of systemic corticosteroids for more severe disease.(1) Recently, other
treatment options for EoE have been investigated including mast cell inhibitors, leukotriene
receptor antagonists, immune modulators and diet modification. There is, as yet, no
universal approach to treatment.(9)
Little is known regarding real-world practices in the diagnosis and management of EoE. It is
unclear whether most gastroenterologists follow the consensus guidelines when making a
diagnosis of EoE. Further, in the setting of several treatment options and limited evidence,
therapy for EoE may be heterogeneous. To date, no study has assessed the practice patterns
of gastroenterologists in the United States who diagnosis and treat EoE and compared these
practices with the guidelines. Understanding these practice patterns has the potential to
identify areas in need of continuing education and to guide future research and guideline
development. The purpose of this study was to assess academic and community practice
patterns for the evaluation and treatment of eosinophilic esophagitis and to compare these
practices with the current guidelines.
Methods
Study Design
This was a prospective study of academic and community gastroenterologists using a self-
administered online survey. The survey was conducted between March 2010 and May 2010.
This study was approved by the University of North Carolina Institutional Review Board.
All participants consented to study participation.
Survey Design
The survey was composed of twenty-five questions which assessed four categories: (1)
symptoms and endoscopic findings of EoE, (2) diagnosis of EoE, (3) treatment of EoE, and
(4) respondent characteristics (see Online Appendix). The survey was piloted prior to the
primary study to assess comprehensibility and comprehensiveness.
Study Population and Survey Administration
In order to assess findings across a spectrum of practice patterns, we surveyed two provider
groups. The first was a sample of academic gastroenterologists primarily in adult patients
from referral centers across the United States who concentrate in esophagology or
international EoE experts. They were identified by their peer-reviewed publication record
and/or national presentations related to research in esophageal disease, including EoE. The
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second group was a random sample of practicing North Carolina adult gastroenterologists
identified through activity in state university-run continuing medical education programs.
Potential subjects were emailed an Institutional Review Board approved invitation to
participate and a link to the survey. The survey could only be accessed via an email link and
could only be completed once. Two follow-up e-mail reminders to participate were also
sent. All responses were anonymous. No incentives to participate were provided.
Analysis
Means and standard deviations are reported for continuous variables. Proportions are
reported for categorical data. To compare respondents’ characteristics, we used a 2 sample t-
test, the Pearson’s chi-square test or the Fisher’s Exact Test, as appropriate. To assess
respondent’s criteria for diagnosis, we asked “Which of the following do you require to
make the diagnosis of EoE?” The respondent checked the answer (s) they felt most
appropriate from a list of individual criteria including: consistent symptoms, positive
endoscopy findings, positive biopsy findings, no clinical response to a PPI trial, no
histologic response to a PPI trial, and negative pH and testing (see Appendix). Individual
components were combined for the analysis. All tests of significance were two-tailed and
alpha values <0.05 were considered significant. Analyses were performed with STATA
software, version 11.0 (College Station, Texas).
Results
We distributed 190 surveys. Of the academic gastroenterologists, 34 of 57 completed the
survey (60% response rate) and of the community gastroenterologists, 38 of 133 completed
the survey (29% response rate). Respondent characteristics are detailed in Table 1. As
expected, all of the academic gastroenterologists identified themselves as sub-specialized in
esophageal disease or therapeutic endoscopy compared with 37% of the community
gastroenterologists (p≤0.001). Academic gastroenterologists report caring for a greater
volume of EoE patients per month compared with community gastroenterologists (mean 6 ±
8 vs. 2 ± 2; p=0.005). Academic gastroenterologists were also more likely to report that they
were “very familiar” with the EoE consensus guidelines than community gastroenterologists
(47% vs. 19%; p=0.01). Academic and community gastroenterologists did not differ
significantly in years of practice (mean 14 ± 10 vs. 17 ± 10; p=NS).
Symptoms and Endoscopic Findings of EoE
A similar proportion of academic and community gastroenterologists identified heartburn,
refractory reflux, chest pain, dysphagia, and food impaction as symptoms that would make
them consider the diagnosis of EoE (Table 2). Significantly more academic
gastroenterologists identified regurgitation as a symptom of EoE compared with community
gastroenterologists (24% vs. 5%; p=0.03).
A similar proportion of academic and community gastroenterologists identified esophageal
rings, esophageal strictures, narrow caliber esophagus, linear furrows, mucosal tears after
passing the endoscope and normal appearing esophagus as endoscopic findings that would
make them consider the diagnosis of EoE (Table 2). However, more academic
gastroenterologists identified decreased mucosal vascularity (27% vs. 5%; p=0.01),
congested esophageal mucosa (24% vs. 3%; p=0.007) and white plaques (97% vs. 76%;
p=0.01) as possible endoscopic findings of EoE compared with community
gastroenterologists.
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The consensus guidelines for EoE suggest that a diagnosis of EoE should be made when a
patient presents with: 1) symptoms of esophageal dysfunction, 2) an esophageal biopsy
demonstrates 15 or more eos/hpf, and 3) there is an absence of competing causes such as
GERD. (1) Less than a quarter of academic gastroenterologists use all three components of
the guideline recommendation to make a diagnosis of EoE, while only 3% of community
gastroenterologists use all three (24% vs. 3%; p=0.007) (Table 3). Of all of the
gastroenterologists surveyed, 44% make a diagnosis of EoE with limited criteria –
specifically, 15% require only a positive biopsy, 19% require symptoms and a positive
biopsy, and 10% require positive endoscopy findings and a positive biopsy. In addition, 51%
require at least a positive endoscopic finding to make a diagnosis of EoE. A third of
gastroenterologists surveyed (44% academic, 18% community; p=0.02) require that a patient
is on a PPI prior to making the diagnosis of EoE with only 55% of those treating twice daily
(Table 3). Just 25% required either a response to PPIs or a negative pH study to make a
diagnosis of EoE.
The majority of all gastroenterologists surveyed (60%) do not use the currently
recommended 15 eos/hpf as their cut-off point for a diagnosis of EoE. Academic
gastroenterologists did use the threshold more frequently than community
gastroenterologists (59% vs. 24%; p=0.002) (Figure 1b). In contrast, 61% of community
gastroenterologists use a threshold equal to or greater than 20 eosinophils per high power
field. A notable proportion of academic and community gastroenterologists report that they
do not use a specific threshold for making a diagnosis of EoE (21% vs. 13%; p=NS).
For biopsy procurement, consensus guidelines recommend multiple biopsies throughout the
esophagus.(1) There was heterogeneity in biopsy practices among both academic and
community gastroenterologists. The majority of both academic and community
gastroenterologists biopsy from multiple locations throughout the esophagus when
considering a diagnosis of EoE (100% vs. 92%; p=NS) (Table 3). Specific biopsy locations,
however, vary greatly (Table 3). The majority of academic and community
gastroenterologists take between 4 and 8 biopsies when considering a diagnosis of EoE
(76% vs. 92%; p=NS) (Figure 1a). Academic gastroenterologists are more likely to take 9 or
more biopsies compared with community gastroenterologists (21% vs. 5%; p=0.05). They
are also more likely to put their biopsies from different locations in different pathology jars
than community gastroenterologists (79% vs. 53%; p=0.02).
EoE Therapy
For treatment, guidelines recommend swallowed topical corticosteroids for mild to moderate
cases or a finite course of systemic corticosteroids for more severe disease.(1) Half of the
gastroenterologists surveyed (53% academic, 56% community; p=NS) use a swallowed
topical steroid from an inhaler for first line treatment of EoE (Table 4). Of those, the
majority of both academic and community gastroenterologists use a total daily dose of
880mcg (53% v 48%; p=NS) or 1760mcg (29% v 14%; p=NS), consistent with consensus
guidelines (Figure 2a). A notable proportion use a total daily dose of less than 880mcg per
day (12% v 24%; p=NS) or greater than 1760mcg per day (6% v 14%; p=NS). There is also
variability in the duration of swallowed topical steroid treatment −59% of
gastroenterologists treat for 6–8 weeks, 27% less than 6 weeks and 15% more than 8 weeks
(Figure 2b). Approximately one-third of gastroenterologists surveyed (33% academic, 30%
community; p=NS) prescribe a PPI as first line treatment for EoE (Table 4).
Of the gastroenterologists who prescribe a PPI as first line therapy, all (100%) prescribe a
swallowed topical steroid for second line treatment of EoE. Of the gastroenterologists who
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prescribe a swallowed steroid as first line therapy, there is substantial variation in practice
with regards to second line therapy. Specifically, 29% prescribe systemic steroids for second
line therapy, 22% prescribe swallowed steroids in a liquid form, 26% prescribe diet
modification, 10% prescribe a PPI and 7% prescribe montelukast (Table 4).
Regarding the use of dilation in the setting of EoE, consensus guidelines recommend
esophageal dilation for symptomatic patients who present with fixed strictures causing
impaction. Academic and community gastroenterologist do not differ significantly in their
endoscopic treatment of EoE, although a sizable portion of each group demonstrates
reluctance to dilate such patients. Approximately one half of gastroenterologists (academic
53% vs. community 63%; p=NS) would perform esophageal dilation for a patient with
suspected EoE in the event of a critical stricture and symptoms of dysphagia (Online Table
5).
Consensus guidelines recommend that the treatment of EoE should initially target symptom
improvement.(1) However, further endoscopic surveillance can be considered in patients
willing to accept treatment based on these results.(1) To monitor response to EoE therapy,
community gastroenterologists more frequently assess only a patient’s symptoms compared
with academic gastroenterologists (86% vs. 50%; p=0.001) (Table 6). In contrast, 47% of
academic gastroenterologists monitor and assess response to therapy with a combination of
patient symptoms, endoscopic and/or biopsy findings (Online Table 6).
Discussion
EoE is a poorly understood disease with what appears to be a rapidly evolving
epidemiology. Practitioners initially struggled with heterogeneous disease definitions, and
they are now limited by an underdeveloped literature and the need for additional education.
Although consensus guidelines for the diagnosis and treatment of EoE have been published,
it has long been unclear whether the diagnosis and management of these patients conformed
to those guidelines. While our a priori hypothesis was that real-world practices would
strongly diverge from consensus guidelines, we were surprised to find the magnitude of this
divergence in both academic subspecialists and community practitioners.
We designed our study sample to enroll academic gastroenterologists who sub-specialized in
esophageal disease and community gastroenterologists. Not surprisingly, these academic
gastroenterologists care for a greater volume of EoE patients than community
gastroenterologists and report greater familiarity with the consensus guidelines. Despite
these differences, both the academic and community gastroenterologists deviated
substantially from the recommendations of the consensus guidelines. Specifically, actual
diagnostic practice diverges from the guidelines in three respects. First, few
gastroenterologists formally exclude GERD. Second, the majority of gastroenterologists use
a threshold of 20 or greater eos/hpf. Finally, many gastroenterologists require positive
endoscopic finding to make a diagnosis of EoE, when endoscopic findings are not part of the
current diagnostic criteria. Among those surveyed, there was no predominant diagnostic
practice.
Why so few gastroenterologists follow the consensus guidelines for the diagnosis of EoE is
unclear. It is possible that gastroenterologists are not familiar with the guidelines.
Alternatively, some gastroenterologists may not agree with the diagnostic criteria
recommended by the consensus guidelines. There is ongoing controversy about the
relationship between EoE and GERD and whether GERD truly needs to be excluded to
diagnose EoE. (10–12) Further, the recommendation of a threshold of 15 eosinophils per
high power field also remains controversial.(1) These debates aside, it is well accepted that
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an endoscopically normal appearing esophagus does not preclude the diagnosis of EoE.(1, 8,
13) Nonetheless, our data show many gastroenterologists insist on endoscopic findings for
the diagnosis of EoE. This finding suggests that it is lack of knowledge of the literature,
rather than a careful weighing of evidence and rejection of the guidelines, that explains the
poor adherence to the published guidelines.
The considerable variability in diagnostic criteria has important implications beyond the
creation of a heterogeneous population of patients with a diagnosis of EoE. Patients with
GERD may be falsely diagnosed with EoE and receive unnecessary and unhelpful steroids.
Similarly, patients with EoE may be falsely diagnosed with GERD and exposed to the risks
of GERD treatment, up to and including inappropriate anti-reflux surgery.(14) The risks and
costs of a missed diagnosis of EoE are unknown.
In addition to variability in diagnostic practices, there were also differences in approaches to
treatment. The majority of gastroenterologists use a swallowed topical steroid from an
inhaler for first line treatment of EoE. While there is no universally accepted approach to the
treatment of EoE, this practice is consistent with the consensus guidelines as well as data
from small clinical trials. (1, 15–19) The differences in dose and duration of treatment are
not surprising and are reflected in the variability in the literature. A notable proportion of
respondents choose a PPI as first line treatment for EoE. This may be evidence that
gastroenterologists misunderstand the importance of ruling out GERD or the timing of the
PPI in relation to a diagnosis of EoE. Alternatively, there is controversy regarding the role of
acid and PPIs in EoE. (10–12) Some authors have suggested that PPIs may have efficacy for
EoE via an anti-inflammatory effect.(12, 20) For second line medical therapy, responses
mirror the myriad options that have been reported for EoE. The lack of a consistent practice
is understandable given that there are very few data to guide therapeutic decision-making in
EoE patients that do not respond well to steroid therapy or PPI.
There has been one prior study of practice patterns in EoE but this was prior to the
publication of the consensus guidelines.(21) In that survey of international adult and
pediatric gastroenterologists, including trainees, King and colleagues found that the majority
of their respondents biopsy both at proximal and distal locations within theesophagus when
a diagnosis of EoE is being considered, use a threshold of 20 eosinophils per high power
field to make a diagnosis of EoE and use fluticasone for treatment of EoE. Because the study
population and specific questions differ between this study and ours, it is difficult to directly
compare the results. However, a finding common to both studies was heterogeneity in
diagnostic and therapeutic practices for this disease state.
Several limitations of our study deserve mention. First, gastroenterologists may have
attempted to respond to questions with perceived correct answers or may have referred to
the literature. Thus, the results of our study may not reflect actual decision making in
clinical practice of those actually surveyed. If our results do reflect the use of the literature
to respond, then one might expect such efforts to bias our data toward the more “correct”
answers, with respect to compliance with the published guidelines – a concerning prospect,
given the findings of our study. Second, in any study relying on surveys, a decrease in
response rate threatens the validity of the study. Physician response rate to questionnaires is
notoriously low, and our response is similar to other published questionnaire based studies
in gastroenterology. (21–24) Finally, because we primarily surveyed adult
gastroenterologists, the results cannot be directly applied to practice patterns of pediatric
gastroenterologists.
In summary, there was a large degree of heterogeneity in the diagnosis and management of
subjects with EoE both in community and sub-specialty GI practice. In many instances, both
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groups reported practices that did not conform to the current guidelines. A large proportion
of gastroenterologists do not rule out GERD prior to making a diagnosis of EoE, use a
threshold of 20 or greater eosinophils per high power field, and/or require positive
endoscopic finding to make a diagnosis of EoE. These results suggest that ongoing
education and research concerning diagnosis and treatment of EoE is needed regardless of
the practice setting.
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Figure 1a. Number of esophageal biopsies obtained when considering EoE diagnosis. The
proportion of academic gastroenterologists obtaining biopsies are in dark bars, and the
community gastroenterologists are in light bars. While there was heterogeneity in the
number of biopsies taken overall, academic gastroenterologists are more likely to take 9 or
more biopsies compared with community gastroenterologists.
Figure 1b. Threshold of eosinophils per high power when making a diagnosis of EoE.
Academic gastroenterologists are in dark bars and community gastroenterologists are in light
bars. Of the multiple cut-points reported, academic gastroenterologists are more likely to use
a threshold of 15 eosinophils per high-power field.
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Figure 2a. Total daily dose fluticasone. Academic gastroenterologists are in dark bars and
community gastroenterologists are in light bars. While there is a range of doses used, there
are no differences between the two provider groups.
Figure 2b. Duration of fluticasone therapy. Academic gastroenterologists are in dark bars
and community gastroenterologists are in light bars. While there is a range in the length of
therapy prescribed, there are no differences between the two provider groups.
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34) Community GI (n=38) p-value*
Years in practice (mean ± s.d.) 16 ± 10 14 ± 10 17 ± 10 NS
Sub-specialized in esophageal disease and/or
therapeutic endoscopy (%)
67% 100% 37% ≤ 0.001
General GI practice (%) 29% 3% 53% ≤ 0.001
“Very familiar” with EoE consensus guidelines (%) 33% 47% 19% 0.01
EoE patients per month (mean ± s.d.) 4 ± 6 6 ± 8 2 ± 2 0.005
EoE, eosinophilic esophagitis; GI, gastroenterologist; NS, not significant
*
Comparison between academic and community GI performed with 2 sample t-test, Pearson’s chi-square test or Fisher’s Exact Test
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Table 2
EoE Diagnosis -Symptoms and Endoscopic Findings
All Respondents (n= 72) Academic GI (n= 34) Community GI (n=38) p-value*
What symptoms would make you consider the diagnosis of EoE:
Heartburn (%) 39% 47% 32% NS
Regurgitation (%) 14% 24% 5% 0.03
Refractory reflux (%) 53% 65% 42% NS
Chest pain (%) 57% 56% 58% NS
Abdominal pain (%) 6% 6% 5% NS
Dysphagia (%) 97% 97% 97% NS
Odynophagia (%) 38% 32% 42% NS
Food impaction (%) 94% 97% 92% NS
Nausea (%) 8% 6% 11% NS
Vomiting (%) 10% 12% 8% NS
Weight loss (%) 14% 12% 16% NS
What endoscopic findings do you consider consistent with the diagnosis of EoE:
Esophageal rings (%) 99% 100% 97% NS
Esophageal stricture (%) 56% 65% 47% NS
Narrow caliber esophagus (%) 76% 85% 68% NS
Linear furrows (%) 99% 100% 97% NS
White plaques/exudates (%) 86% 97% 76% 0.01
Erosive esophagitis (%) 6% 9% 3% NS
Decreased mucosal vascularity (%) 15% 27% 5% 0.01
Congested esophageal mucosa (%) 13% 24% 3% 0.007
Mucosal tears after passing the endoscope (%) 86% 85% 87% NS
Hiatal hernia (%) 1% 3% 0% NS
Normal appearing esophagus (%) 50% 50% 50% NS
EoE, eosinophilic esophagitis; GI, gastroenterologist; NS, not significant
*
Comparison between academic and community GI performed Pearson’s chi-square test or Fisher’s Exact Test



















34) Community GI (n=38) p-value *
Do you put biopsies from different locations in
different pathology jars: (% yes)
65% 79% 53% 0.02
From where in the esophagus do you take biopsies:
Proximal + Middle + Distal (%) 44% 47% 42% NS
Proximal + Distal (%) 33% 44% 24% NS
Middle + Distal (%) 14% 6% 21% NS
Proximal + Middle (%) 4% 3% 5% NS
Middle only (%) 4% 0% 8% NS
Do you require that a patient is on a PPI prior to
making the diagnosis of EoE: (% yes)
31% 44% 18% 0.02
 If yes, do you use once daily or twice daily dosing?
  Once daily 45% 53% 29% NS
  Twice daily 55% 47% 71% NS
 If yes, what is the duration of treatment?
  Range (weeks) 4 –12 4 –8 4 –12
  Mean ± s.d. 6 ± 2 6 ± 2 6 ± 3 NS
Which of the following do you require to make the diagnosis of EoE:
Positive biopsy only 15% 9% 21% NS
Consistent symptoms only 0% 0% 0% NS
Consistent symptoms + Positive biopsy 19% 24% 16% NS
Positive endoscopy findings + Positive biopsy 10% 3% 16% NS
Consistent symptoms + Positive Biopsy + One of the
following: No clinical response to a PPI, No
histologic response to a PPI, and/or Negative pH
testing**
13% 24% 3% 0.007
Consistent symptoms + Positive endoscopy findings
+ Positive biopsy + One of the following: No clinical
response to a PPI, No histologic response to a PPI,
and/or Negative pH testing
15% 15% 16% NS
Consistent symptoms + Positive endoscopy findings
+ Positive biopsy
26% 27% 26% NS
EoE, eosinophilic esophagitis; GI, gastroenterologist; NS, not significant
*
Comparison between academic and community GI performed with 2 sample t-test, Pearson’s chi-square test or Fisher’s Exact Test
**
EoE Consensus Guidelines
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Table 4
EoE Medical Treatment
All Respondents (n= 72) Academic GI (n= 34) Community GI (n=38) p-value *
What is your first line of therapy for treating EoE:
Proton pump inhibitor once daily 14% 9% 19% NS
Proton pump inhibitor twice daily 17% 24% 11% NS
Swallowed topical steroid from an inhaler (ie
fluticasone)
54% 53% 56% NS
Swallowed topical steroid in liquid form (ie
budensonide)
0% 0% 0% NS
Swallowed topical steroid in a thickened liquid
form (ie budesonide slurry)
3% 3% 3% NS
Systemic steroid (ie prednisone) 0% 0% 0% NS
Empiric dietary elimination therapy 1% 3% 0% NS
Targeted dietary elimination therapy based on
allergy testing
3% 3% 3% NS
Elemental diet 0% 0% 0% NS
Leukotriene antagonist (ie montelukast) 3% 0% 6% NS
Immunomodulator (ie 6MP or azathioprine) 0% 0% 0% NS
Biologic (ie infliximab or mepolizumab) 0% 0% 0% NS
Other 4% 6% 3% NS
All Respondents (n= 41) Academic GI (n= 19) Community GI (n=22) p-value *
Of gastroenterologists who prescribe swallowed steroid first line, what is your second line therapy for EoE in patients who do not respond to
initial therapy:
Proton pump inhibitor once daily 5% 5% 5% NS
Proton pump inhibitor twice daily 5% 5% 5% NS
Swallowed topical steroid from an inhaler (ie
fluticasone)
5% 0% 9% NS
Swallowed topical steroid in liquid form (ie
budensonide)
10% 11% 9% NS
Swallowed topical steroid in a thickened liquid
form (ie budesonide slurry)
12% 16% 9% NS
Systemic steroid (ie prednisone) 29% 32% 27% NS
Empiric dietary elimination therapy 7% 11% 5% NS
Targeted dietary elimination therapy based on
allergy testing
17% 16% 18% NS
Elemental diet 2% 5% 0% NS
Leukotriene antagonist (ie montelukast) 7% 0% 13% NS
Immunomodulator (ie 6MP or azathioprine) 0% 0% 0% NS
Biologic (ie infliximab or mepolizumab) 0% 0% 0% NS
Other 0% 0% 0% NS
EoE, eosinophilic esophagitis; GI, gastroenterologist; NS, not significant
*
Comparison between academic and community GI performed Pearson’s chi-square test or Fisher’s Exact Test
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Table 5
Endoscopic Therapy for EoE
All Respondents (n=
72) Academic GI (n= 34) Community GI (n=38) p-value *
If you see an esophageal stricture when doing an endoscopy for a patient with suspected EoE, would you perform dilation at that initial
endoscopy?
Yes – always. 10% 12% 8% NS
Yes – but only if it is a critical stricture and the
patient is having dysphagia.
58% 53% 63% NS
No – I would wait to confirm the diagnosis and
perform dilation after the patient is on treatment
but still having symptoms.
32% 35% 29% NS
No – never. 0% 0% 0% NS
If you perform a dilation, what method would you typically use?
Wire-guided dilator (ie Savary) 28% 35% 21% NS
Through-the-scope balloon 63% 53% 71% NS
Maloney-dilator 6% 3% 8% NS
Depends on the length of the stricture 4% 9% 0% NS
EoE, eosinophilic esophagitis; GI, gastroenterologist; NS, not significant
*
Comparison between academic and community GI performed with Pearson’s chi-square test or Fisher’s Exact Test
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Table 6
Response to Therapy
All Respondents (n= 72) Academic GI (n= 34) Community GI (n=38) p-value *
How do you monitor response to therapy:
Assess patient symptoms only 69% 50% 86% 0.001
Repeat endoscopy and assess endoscopic
findings only
3% 3% 3% NS
Repeat endoscopy and assess biopsy findings
only
6% 9% 3% NS
Assess patient symptoms + Endoscopic findings
+ Biopsy findings
11% 21% 3% 0.02
Assess patient symptoms + Biopsy findings 7% 9% 6% NS
Assess patient symptoms + Endoscopic findings 3% 6% 0% NS
Assess endoscopic + Biopsy findings 1% 3% 0% NS
Do you consider a response to therapy:
Resolution of symptoms only 66% 53% 78% 0.03
Resolution of endoscopy findings only 0% 0% 0% NS
Improvement in histology only (ie eosinophils
present but less than initially)
4% 6% 3% NS
Normalization of histology only (ie no
eosinophils on biopsy)
3% 3% 3% NS
Resolution of symptoms + Improvement or
Normalization of histology
15% 18% 13% NS
Resolution of symptoms + Resolution of
endoscopy findings + Improvement or
Normalization of histology
11% 21% 3% 0.02
In patients who respond to therapy, do you use maintenance therapy:
Yes 31% 32% 31% NS
Sometimes 56% 53% 58% NS
No 13% 15% 11% NS
EoE, eosinophilic esophagitis; GI, gastroenterologist; NS, not significant
*
Comparison between academic and community GI performed with Pearson’s chi-square test or Fisher’s Exact Test
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